Type 2 Diabetes Clinical Trial
Official title:
Effects of 3 Months of Supervised Exercise Training on Cardiometabolic and Inflammatory Biomarkers According to Glucose Tolerance (Normal, Intolerance and Type 2 Diabetes): Measures in Unstimulated and Stimulated Conditions
Verified date | May 2011 |
Source | University Hospital, Clermont-Ferrand |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
The incidence of type 2 diabetes is increasing worldwide. Because of cardiovascular
morbidity and mortality associated with type 2 diabetes, it is imperative to propose methods
of prevention and this in early stage of abnormal glucose metabolism.
This study will assess the beneficial effects of physical activity (acute and chronic
effects) (the subjects being their own controls) on cardiometabolic and inflammatory
biomarkers in 3 conditions : unstimulated (fasting and resting conditions) and stimulated
conditions: postprandial response to a standardized meal preceded or not by an exercise
bout.
The investigators hypothesized that an acute bout of exercise will decrease the postprandial
inflammatory response to a standardized meal and that this effect of exercise will be
increased after 3 months of exercise training.
Status | Active, not recruiting |
Enrollment | 45 |
Est. completion date | February 2012 |
Est. primary completion date | August 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 30 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Male Caucasian Adults between 30 and 65 years old Sedentary criteria based on the determination of fasting glucose (WHO 1999): - normal if fasting plasma glucose (FPG) <1.10 g / l - diabetes if fasting glucose> 1.26 g / l (7 mmol / l) twice - nondiabetic fasting hyperglycemia: 1.10 g / l = FPG = 1.26 g / l - glucose intolerance : if plasma glucose at 120 minutes during the OGTT (75g) is between 1.40 g / l and 2 g/ l. Body mass index 25 BMI 35kg/m2 Affiliated to National Health Insurance Subject giving his written informed consent Subject considered as normal after clinical examination and medical questionnaire Exclusion Criteria: - - drugs that interfere with the parameters determined - diabetic treated with insulin, glitazones or glinides - eating disorders like bulimia and vomiting - special diet, vegan or vegetarian - autoimmune disease or inflammatory progressive desease requiring prolonged treatment - regular physical activity (> 1 hour of physical activity per week for at least 6 months) - smoking (> 5 cigarettes / day) - weight change greater than 5% of the total weight in the 3 months preceding the study - contra-indication to physical activity - chronic pathologies: cancer, inflammatory, cardiac, pulmonary, renal, gastrointestinal or liver diseases - Being in exclusion on the National Volunteers Data file - No one under guardianship or not subject to social security. - Being under someone's supervision - Subjects deprived of their liberty by judicial or administrative. - Refusal to sign the information sheet and written consent for particip |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand | Centre de Recherche en Nutrition Humaine d'Auvergne |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | supervised physical training on cardiometabolic and inflammatory biomarkers | after 3 months | Yes | |
Secondary | relationships between cortisol secretion and the postprandial inflammatory responses depending on the level of glucose tolerance | after 3 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |